Stem cells and cancer cells have enough molecular similarities that the former can be used to trigger immunity against the latter.
An experimental technique removes T cells that aid in vitro tumor growth.
April 1, 2017|
© GEORGE RETSECK
Tumors (purple cells) recruit abnormally high numbers of potently immune-suppressing Tregs, which repress effector T cells (1) and prevent cancer destruction. Addition of anti-TNFR2 monoclonal antibodies (2) targets and kills TNFR2-expressing Tregs, thereby boosting the activity of effector T cells, which attack the tumor (3). The antibodies can also directly kill tumor cells that express the TNFR2 receptor.
Read the full story.
June 5, 2017
Hi Edisson. Thanks for your interest! You can find the full story here: https://www.the-scientist.com/?articles.view/articleNo/49008/title/Targeting-Tregs-Halts-Cancer-s-Immune-Helpers/.
Thanks for reading!
Jef Akst, senior editor, The Scientist